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Reply to D.J. Sargent et al
We appreciate the response from Sargent et al1 to our
correspondence2 and the opportunity to further discuss how to
optimize the use of adjuvant chemotherapy after colon cancer
surgery. Sargent et al agree with our comments for stage II, but
disagree with our comments for stage III cancer. What we stated
was not that adjuvant therapy should be omitted in stage III, but
that it could be omitted for some patients. It is no longer ap-
propriate to simply group patients into stage II or stage III, as we
noted in our correspondence. Treatment has advanced and we
must consider the individual’s risk of recurrence and deﬁne the
need for adjuvant therapy on the basis of pathology factors such
as tumor stage, nodal stage, tumor-node substages, degree of
differentiation, vessel and nerve inﬁltration, extramural depth of
invasion, number of nodes sampled, and quality of the surgical
specimen. Patient and clinical factors such as age, quality of care
provided, elective and emergency surgery, pre- and postoperative
carcinoembryonic antigen levels, and microsatellite instability
are required. In the near future, molecular and immune markers
will also be required. The relative importance of each of these
factors is not precisely known, and some vary considerably
between hospitals; however, by using them, we can better stratify
patients according to their individual risk. Some patients with
stage II will have a much higher risk of recurrence than some
patients with favorable stage III. The need for treatment will
thus be greater in some stage II patients than in some stage III
patients. For example, patients with a stage II pT4bN0 tumor
(zero of eight nodes) and extramural vascular invasion–positive
microsattelite stable have a much higher risk of recurrence than
patients with a stage III pT3aN1 tumor (one of 29 nodes) and
extramural vascular invasion–negative MSS. Because knowl-
edge of response predictors is limited, the indication for
providing adjuvant therapy is the risk of recurrence.
Knowledge about howmuch lower the recurrence risk is today
compared with when the trials were run is limited for any par-
ticular stage. A systematic overview could not ﬁnd such patient
series.3 A report by Tsikitis et al4 gives results in a large series with
lower recurrence rates than seen before; however, as stressed by
Sargent et al,1 results can be confounded by adjuvant therapy
some patients received. The Adjuvant Colon Cancer End Points
(ACCENT) database, of great value for many research questions, does
not provide any information on results that are reached today. Even
if the hospitals were considered to be among the best, the quality of
their details about care, and thus outcome during the 1990s, is
inferior to that of current standards. Recurrence risks overall and
by stage are much lower today than they were in the past when
trials showing improvements in recurrence risk were run. In the
Shi et al5 article from the ACCENT database, a tendency toward
fewer recurrences was seen in patients in trials between 1995 and
2002, which supports our notion, but patients still did not have the
standard of care they would have today. The focus on improved
colon cancer care on a national level in Sweden since about 2004,6
including better preoperative workup, improved surgery with the
concept of complete mesocolic excision, and better pathology,
might at least partly explain why relative survival was signiﬁcantly
superior to that in six other European countries.7 Even without
that speciﬁc focus, survival has clearly improved since 2001 in
one of the other countries (Denmark) that participated in the
comparison.8
It is also important that we discuss absolute gains and not
relative gains at multidisciplinary team conferences and with
patients. This precision medicine is tailored to individual risk
and uses all of the patient’s information, not simply stage II or
stage III. In the near future, we will have access to a wide range of
additional factors that affect the risk of recurrence, so we must
rigorously and effectively assess their value with respect to
current patient information to help us accurately predict risk and
site of recurrence in an individual patient.
For the record, from the 2,031 patients in the QUASAR
(Leucovorin and Fluorouracil Compared With Observation in
Treating Patients With Colorectal Cancer That Has Been Sur-
gically Removed) study, in which information was available on
lymph node numbers, the median yield was 9 and the mean
was 10.7 lymph nodes (Hutchins G, personal communication),
and not 6 as stated in the correspondence. However, this in-
formation is insufﬁcient according to present standards.
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